TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01585064

Intervention type: OTHER
Intervention: DAS28-IOMS
Description: Investigators randomized to DAS28-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a DAS28 score of \< 2.4.

Intervention type: OTHER
Intervention: 0SJ-IOMS
Description: Investigators randomized to 0SJ-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a swollen joint count of 0.

Intervention type: OTHER
Intervention: Routine Care (RC)
Description: Investigators randomized to RC will NOT be expected to adapt their therapeutic approaches to a pre-defined target. They will optimize adalimumab treatment according to individual patient's responses to treatment as per routine care and according to their own judgment.
Study: NCT04426019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLS Intervention
Description: Community health workers (or promotoras) will deliver the CLS program either in face-to-face and/or group sessions to all women within 2 months of the baseline interview. Each session will last approximately 1 to 2 hours, and will include CLS materials adapted for this study.At the conclusion of the CLS program, promotoras will provide information about local and affordable providers delivering low-cost or free breast and cervical cancer screening services. Should a woman require follow-up for abnormal results, referrals will be given to programs,which provides assistance accessing cancer diagnostic and treatment services. Two weeks after delivering the education component of the CLS program, promotoras will call women to provide any further assistance needed. During these follow-up calls promotoras will provide on-going navigation support to women in need of mammography and Pap test screening

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No CLS intervention
Description: This control arm will receive only usual practice care (print education) and will not receive the CLS intervention. They may receive the intervention after the study has been completed
Study: NCT01076595

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Betaferon 250 microgram
Study: NCT00803894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK0752
Description: Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: MK0752.
Description: Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Single dose placebo capsules: there will be a 7-day washout period between treatments.
Study: NCT04057118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703
Description: Oral administration, twice per day
Study: NCT01252251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 (Everolimus) and Pasireotide (SOM230) LAR
Description: Patients will be treated with SOM-230 (pasireotide) LAR 60mg IM once every 28 days and with RAD001 (Everolimus) 10mg PO daily. Each cycle is 28 days. An optional biopsy may be requested required after weeks of therapy. The biopsy may be performed between days 28 and 42.
Study: NCT06250621

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Implants were placed by means of a template for a guided surgery approach (GD Group) or with a standard free-hand surgical approach without any additional device (FH Group). A non expert doctor (less that 20 implants placed in the professional activity) was selected for the procedures related to the GD Group; a skilled operator (more than 1000 implants placed in the professional activity) was selected for the procedures related to the FH Group, respectively.~A two-stage surgical technique was chosen. Implants were placed (Anyridge, Megagen Implants, Seoul, Korea) 1 mm below the crestal level, as recommended by the manufacturer. After flap elevation the height of the supra-crestal soft tissue (STH) was measured by means of a calibrated probe.~An inter-implant distance of 3 mm at least, and/or an interproximal space from 1.5 to 3 mm between an implant and the adjacent tooth were observed.~Flaps were sutured over the implants to allow a submerged healing.
Study: NCT04057118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703
Description: Oral administration, twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703
Description: Oral administration, twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration, twice per day
Study: NCT00833976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: 4 grams per day
Study: NCT02779179

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal treatment
Description: * Mechanical debridement (scaling, root planning, subgingival curettage)~* Antimicrobial therapy (systematically administered: amoxicillin or clindamycin).~* Antiseptic mouthrinses, gel or dentifrice~* Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: * Mechanical debridement (scaling, root planning, subgingival curettage)~* Antimicrobial therapy (systematically administered: amoxicillin or clindamycin).~* Antiseptic mouthrinses, gel or dentifrice~* Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)
Study: NCT01853449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Study: NCT03725722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application
Study: NCT01853449

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CWS
Description: Chest wall strapping to reduce vital capacity by 20% of its baseline value

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CWS
Description: Chest wall strapping to reduce vital capacity by 20% of its baseline value

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study: NCT03725722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application
Study: NCT01834820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine and Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Study: NCT04199247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sub symptom aerobic exercise
Description: Participants will meet with a member of the research team to undergo a bike-based exercise test at the initial test. Heart rate will be obtained at the completion of the test, and intervention participants will be asked to complete exercise at 80% of that level, 5x/week for 20-30 minutes/session over the next two months.
Study: NCT03725722

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delgocitinib cream vehicle
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Study: NCT00288119

Intervention type: DEVICE
Intervention: Balloon Capsule Device
Description: The Esophageal Sampling Device BESD-001 is a non-endoscopic balloon capsule catheter for obtaining an esophageal mucosal sample. At the distal end of the catheter there is a silicone capsule textured balloon assembly. The textured balloon is initially inverted with vacuum for patient to swallow the capsule but then is inflated with 5.6 cc of air (5 cc syringe withdrawn maximally) to a 16-18 mm diameter in order to contact the lumen of the esophagus to collect a sample. The balloon has a textured surface, which enhances the collection of the esophageal sample. Following sample collection the textured balloon is inverted back into the hollow capsule component via syringe draw vacuum in order to maximize \& protect the site-specific sample collection.

Intervention type: DEVICE
Intervention: Balloon Capsule Device
Description: The Esophageal Sampling Device BESD-001 is a non-endoscopic balloon capsule catheter for obtaining an esophageal mucosal sample. At the distal end of the catheter there is a silicone capsule textured balloon assembly. The textured balloon is initially inverted with vacuum for patient to swallow the capsule but then is inflated with 5.6 cc of air (5 cc syringe withdrawn maximally) to a 16-18 mm diameter in order to contact the lumen of the esophagus to collect a sample. The balloon has a textured surface, which enhances the collection of the esophageal sample. Following sample collection the textured balloon is inverted back into the hollow capsule component via syringe draw vacuum in order to maximize \& protect the site-specific sample collection.
Study: NCT03822169

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline added as a phospholipid
Description: A shake with 3000 mg choline added as a phospholipid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Choline added as a salt
Description: A shake with 3000 mg choline added as a salt
Study: NCT04563858

Intervention type: DIAGNOSTIC_TEST
Intervention: Validation
Description: Assessment of Polish version of the 4AT
Study: NCT02525133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XaraColl
Description: Surgical implantation of 3 bupivacaine collagen implants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Plain collagen implant (vehicle)
Study: NCT00111657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: 8 mg of Pegloticase administered IV every 3 weeks; total number of infusions is 5
Study: NCT02199457

Intervention type: DEVICE
Group type: OTHER
Intervention: SVSS and reference devices
Description: Blood pressure will be measured with standard mercury manometer

Intervention type: DEVICE
Group type: OTHER
Intervention: SVSS and reference devices
Description: Body temperature taken with infrared thermometer

Intervention type: DEVICE
Group type: OTHER
Intervention: SVSS and reference devices
Description: Pulse rate and Sp02 measured with a reference pulse oximter. The pulse oximeter is just clipped to the end of the finger.

Intervention type: DEVICE
Group type: OTHER
Intervention: SVSS and reference devices
Description: Measurement of respiration rate
Study: NCT02691455

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baerveldt Glaucoma Implant 350-mm2 / BG101-350

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transscleral Diode Laser Cyclophotocoagulation
Description: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed Model FP7 Flexible Plate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baerveldt Glaucoma Implant 250-mm2 / BG103-250
Study: NCT04361357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whey protein
Description: whey protein powder was added on the basis of standardized enteral nutrition preparation.
Study: NCT02783404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Receiving 2 gr oral Amoxicillin before dental any manipulation and following endotracheal intubation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Potassium Clavulanate
Description: Receiving 2 gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate
Study: NCT02736162

Intervention type: OTHER
Intervention: No treatment (intervention) was administered
Study: NCT01170780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: single use of dexamethasone IV 8 mg/2 ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2 ml IV
Study: NCT02270580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PN+
Description: we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PN usual
Description: participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
Study: NCT02019719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film coated tablets of GSK1278863 matching placebo for oral administration.
Study: NCT00094380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTLA4-IgG4m (RG2077)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTLA4-IgG4m (RG2077)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT00865527

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal occult blood test
Description: FOBT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual colonoscopy
Description: computed tomographic colonography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Optical colonoscopy
Description: optical (conventional / endoscopic) colonoscopy
Study: NCT02972580

Intervention type: GENETIC
Intervention: Genetic characterization
Description: Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts

Intervention type: GENETIC
Intervention: Genetic characterization
Description: Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts
Study: NCT01874717

Intervention type: OTHER
Group type: OTHER
Intervention: Conscious sedation for dental care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conscious sedation for dental care
Study: NCT00288119

Intervention type: DEVICE
Intervention: Balloon Capsule Device
Description: The Esophageal Sampling Device BESD-001 is a non-endoscopic balloon capsule catheter for obtaining an esophageal mucosal sample. At the distal end of the catheter there is a silicone capsule textured balloon assembly. The textured balloon is initially inverted with vacuum for patient to swallow the capsule but then is inflated with 5.6 cc of air (5 cc syringe withdrawn maximally) to a 16-18 mm diameter in order to contact the lumen of the esophagus to collect a sample. The balloon has a textured surface, which enhances the collection of the esophageal sample. Following sample collection the textured balloon is inverted back into the hollow capsule component via syringe draw vacuum in order to maximize \& protect the site-specific sample collection.

Intervention type: DEVICE
Intervention: Balloon Capsule Device
Description: The Esophageal Sampling Device BESD-001 is a non-endoscopic balloon capsule catheter for obtaining an esophageal mucosal sample. At the distal end of the catheter there is a silicone capsule textured balloon assembly. The textured balloon is initially inverted with vacuum for patient to swallow the capsule but then is inflated with 5.6 cc of air (5 cc syringe withdrawn maximally) to a 16-18 mm diameter in order to contact the lumen of the esophagus to collect a sample. The balloon has a textured surface, which enhances the collection of the esophageal sample. Following sample collection the textured balloon is inverted back into the hollow capsule component via syringe draw vacuum in order to maximize \& protect the site-specific sample collection.

Intervention type: PROCEDURE
Intervention: Endoscopy
Description: An upper endoscopy is a procedure used to visually examine your upper digestive system with a tiny camera on the end of a long, flexible tube.

Intervention type: PROCEDURE
Intervention: Endoscopy
Description: An upper endoscopy is a procedure used to visually examine your upper digestive system with a tiny camera on the end of a long, flexible tube.

Intervention type: PROCEDURE
Intervention: Endoscopy
Description: An upper endoscopy is a procedure used to visually examine your upper digestive system with a tiny camera on the end of a long, flexible tube.

Intervention type: PROCEDURE
Intervention: Endoscopy
Description: An upper endoscopy is a procedure used to visually examine your upper digestive system with a tiny camera on the end of a long, flexible tube.
Study: NCT01376752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maximal cytoreductive surgery
Description: Maximal cytoreductive surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maximal cytoreductive surgery
Description: Maximal cytoreductive surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC: Hyperthermic Intra-PEritoneal Chemotherapy. Administration of cisplatin at 75mg/m²
Study: NCT03561779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYD302 2ml
Description: YYD302 2ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: Synovian Inj.
Description: Active comparator: Synovian Inj.
Study: NCT02172209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 10773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Study: NCT04468295

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bonding
Description: Bonding of upper and lower arches including 2nd maxillary molars with bracket prescription Roth 0.018 inch

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bonding
Description: Bonding of upper and lower arches including 2nd maxillary molars with bracket prescription Roth 0.018 inch

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leveling and alignment
Description: Leveling and alignment till 0.016 x0.022 Ni Ti

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Leveling and alignment
Description: Leveling and alignment till 0.016 x0.022 Ni Ti

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction
Description: Extraction of maxillary 1st premolars

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction
Description: Extraction of maxillary 1st premolars

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retraction
Description: En-masse retraction using 0.017x0.025 TMA T loop

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retraction
Description: En-masse retraction using 0.017x0.025 TMA T loop

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital models
Description: impression taking and digital scanning
Study: NCT05875116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The activities will be carried out with the Virtual Reality team, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, on similar equipment and with the same or similar software, at least 1 hour a day, at least 3 days a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy
Description: Physical and occupational therapy activities will be carried out with the paretic upper limb, while the patient has the healthy upper limb attached to the chest, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, 1 hour a day, at least 3 days a week. In addition, the participant will perform activities of daily living with the free paretic arm and the fixed healthy arm, for 5 hours a day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Physical and Occupational Therapy
Description: The physical and occupational therapy activities that are usually practiced in the Medical Unit will be carried out for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, for 1 hour a day, at least 3 days a week.
Study: NCT03593356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly cash gift payments of $333
Description: These subjects receive $333 each month for 76 months via debit card.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monthly cash gift payments of $20
Description: These subjects receive $20 each month for 76 months via debit card.
Study: NCT01216319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nipple reconstruction
Description: Biodesign® Nipple Reconstruction Cylinder
Study: NCT00852072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-operator cholangioscopy-guided laser lithotripsy
Description: Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Sphincteroplasty
Description: Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
Study: NCT00116207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORAL ANTIOXIDANT
Description: Comparison of triple antioxidant combination therapy vs placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ORAL ANTIOXIDANT
Description: Comparison of triple antioxidant combination therapy vs placebo.